Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05
NCT ID: NCT02795780
Last Updated: 2020-08-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
79 participants
INTERVENTIONAL
2016-08-31
2017-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of Flortaucipir F 18
NCT02278367
18F-AV-1451 Autopsy Study
NCT02516046
18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
NCT02079766
A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects
NCT01992380
Flortaucipir PET Imaging in Subjects With FTD
NCT03040713
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Follow-up Flortaucipir PET Scan
Flortaucipir F18
370 megabecquerel (MBq) IV single-dose
PET Scan
positron emission tomography (PET) scan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flortaucipir F18
370 megabecquerel (MBq) IV single-dose
PET Scan
positron emission tomography (PET) scan
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
* Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
* Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
* Have received or participated in a trial with investigational medications in the past 30 days
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Avid Radiopharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner Alzheimer's Institute
Phoenix, Arizona, United States
Imaging Endpoints
Scottsdale, Arizona, United States
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Banner Sun Health Research Institute
Sun City, Arizona, United States
Institute for Brain Aging and Dementia, UC Irvine
Irvine, California, United States
21st Century Oncology
Newport Beach, California, United States
Alzheimer's Disease Center, UC Davis
Sacramento, California, United States
California Medical Clinic for Headache
Santa Monica, California, United States
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
University of South Florida Health Byrd Alzheimer's Institute
Tampa, Florida, United States
Premiere Research Institute
West Palm Beach, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Boston University School of Medicine
Boston, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
Las Vegas Radiology
Las Vegas, Nevada, United States
New York University Center for Brain Health
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Butler Hospital
Providence, Rhode Island, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18F-AV-1451-A18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.